Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY (MRK)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Merck & Co., Inc. : Merck to Present at Deutsche Bank 37th Annual Health Care Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/08/2012 | 02:15pm CET

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Peter Kellogg, executive vice president and chief financial officer and Nancy Thornberry, senior vice president and franchise head for diabetes and endocrinology are scheduled to present at the Deutsche Bank 37th Annual Health Care Conference in Boston, Mass. on May 9 at 8:00 a.m. EDT. Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at: http://www.merck.com/investors/events-and-presentations/home.html.

About Merck

Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook and YouTube.

Forward-Looking Statement

This news release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such statements may include, but are not limited to, statements about the benefits of the merger between Merck and Schering-Plough, including future financial and operating results, the combined company's plans, objectives, expectations and intentions and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of Merck's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements.

The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the possibility that all of the expected synergies from the merger of Merck and Schering-Plough will not be realized, or will not be realized within the expected time period; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; Merck's ability to accurately predict future market conditions; dependence on the effectiveness of Merck's patents and other protections for innovative products; and the exposure to litigation and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck's 2011 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).

Merck
Media:
Ron Rogers, (908) 423-6449
or
Investors:
Carol Ferguson, (908) 423-4465


© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
07:32a ROCHE : Tecentriq cocktail slows kidney cancer progression
07:03a Merck raises stakes in lung cancer as rivals close in
12/09 EISAI : Updated Analysis of Phase Ib/II Study of Eribulin and Pembrolizumab Comb..
12/08 MERCK AND : New England Journal of Medicine Publishes Phase 3 Clinical Study of ..
12/07 Sage Therapeutics, Dollar General jump; LendingClub tumbles
12/07 Roche drug cocktail doubles chance of holding lung cancer at bay
12/07 DOW MOVERS : Jpm, mrk
12/07 U.K. unveils life sciences sector deal
12/06 MERCK AND : New England Journal of Medicine Publishes Phase 3 Clinical Study of ..
12/06 Roche to seize leap-frog opportunity in lung cancer
More news
News from SeekingAlpha
12/10 BIOTECH IN 2018 : Will Repatriated Cash Fuel A Feeding Frenzy?
12/08 Halaven/Keytruda combo shows 26% response rate in TNBC study
12/08 73 Dividend Growth Stocks Going Ex-Dividend Next Week
12/06 Merck weak ahead of Roche data release from late-stage study of Tecentriq in ..
12/06 3 THINGS IN BIOTECH YOU SHOULD LEARN : December 6, 2017
Financials ($)
Sales 2017 40 235 M
EBIT 2017 13 721 M
Net income 2017 5 246 M
Debt 2017 13 787 M
Yield 2017 3,40%
P/E ratio 2017 27,22
P/E ratio 2018 17,87
EV / Sales 2017 4,11x
EV / Sales 2018 3,99x
Capitalization 152 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 65,4 $
Spread / Average Target 18%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Clark Golestani Chief Information Officer & Executive VP
Roy D. Baynes Chief Medical Officer
Thomas Henry Glocer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY-7.68%151 559
JOHNSON & JOHNSON21.23%377 698
NOVARTIS11.34%218 728
PFIZER9.48%213 036
ROCHE HOLDING LTD.6.19%208 877
AMGEN22.20%127 332